Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625146 | 0.98 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4DHFRCHRNB4 | |
| SCHEMBL6757125 | 0.95 | CHRNB4 (0.50) | SLC6A3SLC6A2SLC6A4DHFRCHRNB4 | |
| SCHEMBL27996273 | 0.87 | SLC6A3 (0.52) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Hydrochloric Acid SCHEMBL4319146 | 0.86 | LTA4H (0.54) | SLC6A3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4319155 | 0.86 | LTA4H (0.54) | SLC6A3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4313832 | 0.86 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Hydrochloric Acid SCHEMBL4313825 | 0.86 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL6800333 | 0.84 | SLC6A3 (0.43) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL3114462 | 0.84 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6698315 | 0.83 | CHRNB2 (0.55) | SLC6A3SLC6A2SLC6A4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891051-A2 | SOLID FORMS OF 1-( 5-(IH-I , 2 , 4 -TRIAZOL- 5 -YL)(1H-INDAZOL-3-YL))-3-(2-PIPERIDYLETHOXY)BENZENE | CELGENE CORPORATION (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006130297-A2 | SOLID FORMS OF 1-( 5-(IH-I , 2 , 4 -TRIAZOL- 5 -YL)(1H-INDAZOL-3-YL))-3-(2-PIPERIDYLETHOXY)BENZENE | CELGENE CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | SLC6A3 464/4885SLC6A2 196/4885SLC6A4 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.